TY - JOUR
T1 - TFAM is a novel mediator of immunogenic cancer cell death
AU - Yang, Minghua
AU - Li, Changfeng
AU - Zhu, Shan
AU - Cao, Lizhi
AU - Kroemer, Guido
AU - Zeh, Herbert
AU - Tang, Daolin
AU - Kang, Rui
N1 - Funding Information:
We thank Christine Heiner (Department of Surgery, University of Pittsburgh) for her critical reading of the manuscript. This work was supported by grants from the US National Institutes of Health (R01GM115366, R01CA160417, and R01CA211070), the Natural Science Foundation of Guangdong Province (2016A030308011), the Natural Science Foundation of Hunan Province (2016JJ3171), the American Cancer Society (Research Scholar Grant RSG-16–014-01-CDD), the National Natural Science Foundation of China (31671435, 81400132, 81772508, and 81570154), Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2017), and Lin He’s Academician Workstation of New Medicine and Clinical Translation (2017). This project partly utilized University of Pittsburgh Cancer Institute shared resources supported by award P30CA047904. GK is supported by the Ligue contre le Cancer Comitéde Charente-Maritime (équipe labelisée); Agence National de la Recherche (ANR) – Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Cancéropôle Ile-de-France; Chancelerie des universités de Paris (Legs Poix), Fondation pour la Recherche Médicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); Fonda-tion Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumière, the Searave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).
Funding Information:
HHS | National Institutes of Health (NIH) (R01GM115366, R01CA160417, and R01CA211070). We thank Christine Heiner (Department of Surgery, University of Pittsburgh) for her critical reading of the manuscript. This work was supported by grants from the US National Institutes of Health (R01GM115366, R01CA160417, and R01CA211070), the Natural Science Foundation of Guangdong Province (2016A030308011), the Natural Science Foundation of Hunan Province (2016JJ3171), the American Cancer Society (Research Scholar Grant RSG-16?014-01-CDD), the National Natural Science Foundation of China (31671435, 81400132, 81772508, and 81570154), Guangdong Province Universities and Colleges Pearl River Scholar Funded Scheme (2017), and Lin He's Academician Workstation of New Medicine and Clinical Translation (2017). This project partly utilized University of Pittsburgh Cancer Institute shared resources supported by award P30CA047904. GK is supported by the Ligue contre le Cancer Comit? de Charente-Maritime (?quipe labelis?e); Agence National de la Recherche (ANR)?Projets blancs; ANR under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canc?rop?le Ile-de-France; Chancelerie des universit?s de Paris (Legs Poix), Fondation pour la Recherche M?dicale (FRM); the European Commission (ArtForce); the European Research Council (ERC); Fondation Carrefour; Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the RHU Torino Lumi?re, the Searave Foundation; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); the SIRIC Cancer Research and Personalized Medicine (CARPEM); and the Paris Alliance of Cancer Research Institutes (PACRI).
Publisher Copyright:
© 2018 The Author(s). Published with license by Taylor & Francis Group, LLC © 2018, © Minghua Yang, Changfeng Li, Shan Zhu, Lizhi Cao, Guido Kroemer, Herbert Zeh, Daolin Tang and Rui Kang.
PY - 2018/6/3
Y1 - 2018/6/3
N2 - Immunogenic cell death (ICD) is a type of cell death that is accompanied by the release of damage-associated molecular patterns (DAMPs) and results in a dead-cell antigen-specific immune response. Here, we report that spautin-1, an inhibitor of ubiquitin-specific peptidases, triggers immunogenic cancer cell death in vitro and in vivo. The anticancer activity of spautin-1 occurs independent of autophagy inhibition, but depends on the intrinsic mitochondrial apoptosis pathway. Spautin-1 causes mitochondrial oxidative injury, which results in JUN transcription factor activation in a JNK-dependent manner. Mechanistically, activation of JUN by spautin-1 leads to apoptosis by upregulation of pro-apoptotic BAD expression. Importantly, the release of TFAM, a mitochondrial DAMP, by apoptotic cells may contribute to spautin-1-induced ICD via its action on the receptor AGER. Indeed, cancer cells treated with spautin-1 in vitro were able to elicit an anticancer immune response when inoculated in vivo, in the absence of any adjuvant. This immunogenic effect of spautin-1-treated cancer cells was lost when TFAM or AGER were neutralized by specific antibodies. Altogether, our results suggest that spautin-1 may stimulate an apoptotic pathway that results in ICD, in TFAM- and AGER-dependent fashion.
AB - Immunogenic cell death (ICD) is a type of cell death that is accompanied by the release of damage-associated molecular patterns (DAMPs) and results in a dead-cell antigen-specific immune response. Here, we report that spautin-1, an inhibitor of ubiquitin-specific peptidases, triggers immunogenic cancer cell death in vitro and in vivo. The anticancer activity of spautin-1 occurs independent of autophagy inhibition, but depends on the intrinsic mitochondrial apoptosis pathway. Spautin-1 causes mitochondrial oxidative injury, which results in JUN transcription factor activation in a JNK-dependent manner. Mechanistically, activation of JUN by spautin-1 leads to apoptosis by upregulation of pro-apoptotic BAD expression. Importantly, the release of TFAM, a mitochondrial DAMP, by apoptotic cells may contribute to spautin-1-induced ICD via its action on the receptor AGER. Indeed, cancer cells treated with spautin-1 in vitro were able to elicit an anticancer immune response when inoculated in vivo, in the absence of any adjuvant. This immunogenic effect of spautin-1-treated cancer cells was lost when TFAM or AGER were neutralized by specific antibodies. Altogether, our results suggest that spautin-1 may stimulate an apoptotic pathway that results in ICD, in TFAM- and AGER-dependent fashion.
UR - http://www.scopus.com/inward/record.url?scp=85042118545&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042118545&partnerID=8YFLogxK
U2 - 10.1080/2162402X.2018.1431086
DO - 10.1080/2162402X.2018.1431086
M3 - Article
C2 - 29872558
AN - SCOPUS:85042118545
SN - 2162-4011
VL - 7
JO - OncoImmunology
JF - OncoImmunology
IS - 6
M1 - e1431086
ER -